Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 7;12:20. doi: 10.1186/s13287-020-02078-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — ANGPTL3 mediates the angiogenic effects of USC-Exo on HUVECs. a, b The mRNA and protein levels of ANGPTL3 were assessed by RT-qPCR and Western blot analysis. c Western blot analysis of ANGPTL3 in HUVECs after USC-Exo treatment. d Western blot analysis of ANGPTL3 in exosomes from ANGPTL3-silenced USC and confirmation of the inhibitory efficiency of shRNA targeting ANGPTL3. e The proliferation of HUVECs treated with PBS, USC-Con shRNA-Exo, and USC-shANGPTL3-Exo. f Quantitative analysis of the proliferation of HUVECs in different treatment groups shown in e. g, i Representative images of tube formation and migration in HUVECs treated with PBS, USC-Con shRNA-Exo, and USC-shANGPTL3-Exo. h, j Quantitative analyses of the total tube length, total branching points, and total loops shown in g and migration area shown in i. k Western blot analysis of the protein expression levels of PI3K/AKT components to assess signaling pathway activation in HUVECs among the different treatment groups. The data are presented as the means ± SD; n = 6 per group. *p < 0.05, **p < 0.01 compared among different treatment groups